Compounds and compositions as protein kinase inhibitors

A compound having Formula (1):

• or pharmaceutically acceptable salts thereof;
• wherein
• W is
• A1 and A4 are independently C or N;
• each A2 and A3 is C, or one of A2 and A3 is N when R6 and R7 form a ring;
• B and C are independently an optionally substituted 5-7 membered carbocyclic ring, aryl, heteroaryl or heterocyclic ring containing N, O or S;
• Z1, Z2 and Z3 are independently NR11, C═O, CR—OR, (CR2)1-2 or ═C—R12;
• R1 is halo or C1-6 alkyl;
• R2 is H;
• R3 is (CR2)0-2SO2R12, (CR2)0-2SO2NRR12, (CR2)0-2CO1-2R12, CO2NH2, (CR2)0-2CONRR12 or cyano;
• R4 and R6 are independently an optionally substituted C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl;
• OR12, NR(R12), halo, nitro, SO2R12, (CR2)pR13 or X;
• or R4, R7 and R10 are independently H;
• R, R5 and R5′ are independently H or C1-6 alkyl;
• R7 and R10 are independently H;
• R8 and R9 are independently C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo or X, or one of R8 and R9 is H when R1 and R2 form a ring;
• and provided one of R8 and R9 is X;
• alternatively, R6 and R7, R7 and R8, or R9 and R10, when attached to a carbon atom may form an optionally substituted 5-7 membered monocyclic or fused carbocyclic ring, aryl, or heteroaryl or heterocyclic ring comprising N, O and/or S;
• or R7, R8, R9 and R10 are absent when attached to N;
• R11 is H, C1-6 alkyl, C2-6 alkenyl, (CR2)pCO1-2R, (CR2)pOR, (CR2)pR13, (CR2)pNRR12, (CR2)pCONRR12 or (CR2)pSO1-2R12;
• R12 and R13 are independently an optionally substituted 3-7 membered saturated or partially unsaturated carbocyclic ring, or a 5-7 membered heterocyclic ring comprising N, O and/or S;
• aryl or heteroaryl;
• or R12 is H, C1-6 alkyl;
• X is (CR2)qY, cyano, CO1-2R12, CONR(R12), CONR(CR2)pNR(R12), CONR(CR2)pOR12, CONR(CR2)pSR12, CONR(CR2)pS(O)1-2R12 or (CR2)1-6NR(CR2)pOR12;
• Y is an optionally substituted 3-12 membered carbocyclic ring, a 5-12 membered aryl, or a 5-12 membered heteroaryl or heterocyclic ring comprising N, O and/or S and attached to A2 or A3 or both via a carbon atom of said heteroaryl or heterocyclic ring when q in (CR2)qY is 0;
• and
• n is 0;
• and
• p and q are independently 0-4.